Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other financing activities Other financing activities Preferred Shares Issued Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Ratios

Spyre Therapeutics (SYRE) Gains from Sales and Divestitures (2018)

Spyre Therapeutics' Gains from Sales and Divestitures history spans 2 years, with the latest figure at $26444.0 for Q4 2018.

For Q4 2018, Gains from Sales and Divestitures changed N/A year-over-year to $26444.0; the TTM value through Dec 2018 reached $26444.0, changed N/A, while the annual FY2018 figure was $26444.0, N/A changed from the prior year.
Gains from Sales and Divestitures reached $26444.0 in Q4 2018 per SYRE's latest filing, down from $32588.0 in the prior quarter.
In the past five years, Gains from Sales and Divestitures ranged from a high of $32588.0 in Q4 2015 to a low of $26444.0 in Q4 2018.